Could Omics Improve Fabry Disease Diagnosis?
Researchers examine how molecular profiling could help identify organ injury that conventional testing may miss
Clinical Scorecard: Could Omics Improve Fabry Disease Diagnosis?
At a Glance
| Category | Detail |
|---|
| Condition | Fabry Disease |
| Key Mechanisms | Variants in the GLA gene reduce alpha-galactosidase A activity, leading to globotriaosylceramide and globotriaosylsphingosine accumulation. |
| Target Population | Patients with Fabry disease, particularly those with renal and cardiac involvement. |
| Care Setting | Clinical and laboratory settings for diagnosis and monitoring. |
Key Highlights
- Multi-omics research may identify biomarkers for Fabry disease diagnosis and monitoring.
- Alpha-galactosidase A activity and Lyso-Gb3 levels are currently used but have limitations.
- Transcriptomics, proteomics, and metabolomics could supplement existing diagnostic approaches.
- Kidney and cardiac involvement are significant areas of focus in Fabry disease research.
- Routine multi-omics testing is not yet supported due to insufficient evidence and practical barriers.
Guideline-Based Recommendations
Diagnosis
- Combine clinical and family history with enzyme activity, Gb3 or Lyso-Gb3 measurements, and genetic testing.
Management
- Monitor organ involvement, particularly in the kidneys and heart.
Monitoring & Follow-up
- Consider molecular profiles alongside traditional diagnostic methods.
Risks
- Renal damage may progress to kidney failure; cardiac complications may arise.
Patient & Prescribing Data
Patients with Fabry disease, especially those with heterozygous variants.
Current treatments may not fully address the complexities of organ involvement.
Clinical Best Practices
- Utilize a combination of biochemical and genetic testing for comprehensive diagnosis.
- Stay updated on emerging biomarkers from multi-omics studies.
Related Resources & Content
